

• Ğ



FIGHT COLORECTAL CANCE









FIGHT CRC BOARD OF DIRECTORS

Board leadership during FY20

NANCY ROACH Founder & Chair of the Board

DR. ANGELA NICHOLAS Vice-Chair

ERIC HAUSMANN Secretary

KATHERINE ZAHNER Treasurer

DANA RYE Director

ROMAINE SEGUIN Director

CARRIE SWEIGART Director

RON DOORNINK Director

TERI GRIEGE Director

STEVE GREENE Director

JOANNA HAYDON Director

DR. RICHARD GOLDBERG Director

DAVID WICKS Emeritus

ANDREA KRAMER Emeritus



Hold your smart phone's camera over this code to meet our staff and volunteer champions!

DEAR RELENTLESS CHAMPIONS OF HOPE,

There couldn't have been a better time to rally around being "relentless" than the past year. We launched our new brand and mission statement in November 2019. We would have never guessed a global pandemic was about to change the world and that "relentless" would take on a whole new meaning for our community.

As champions for hope, we were ready for it. We dug in and stayed mission-focused.

We haven't let anything stop us from moving forward this year. We've continued catalyzing critical conversations and paving a path to a cure. Although COVID-19 forced us to change how we did things, it didn't change our focus.

Thanks to your support, we continued to provide nonstop resources from masks to online programming for patients, caregivers, and loved ones. For our friends on the frontlines, we convened discussions to ensure the science wouldn't stop. I believe leadership in difficult times is as challenging as it is important. Our team came to work ready to serve our community members every day. We faced this year head-on and ready to fight.

Our donors and supporters are the heartbeat of our organization. We depend on your resilience, empathy, and support. Whether you gave to support a climber, donated on Giving Tuesday, participated in No-Shave November, funded innovative research, or sponsored our events, programs, and resources—you made a difference this year.

In a time when it's tempting to conserve all resources and cut back, you chose to put your dollars to work and fight alongside our organization. We hope that as you read through your impact this year, you feel proud. You made our community stronger.

Here is how we've taken every dollar you gave and applied it to patient support, advocacy, and research. Your continued support will ensure we remain the go-to stop for patient resources, catalyze national and state advocacy, and fund innovative research that will lead to a cure.

Thank you for being relentless!

Ayritaris

Sincerely, Anjee Davis, MPPA President



HOW WE FIGHT





OUR MISSION

We FIGHT to cure colorectal cancer and serve as relentless champions of hope for all affected by this disease through informed patient support, impactful policy change, and breakthrough research endeavors.

WHO WE SERVE



(active treatment

& remission)









Reflects opt-ins and followers as of December 2020

LOVED MEDICAL ONES **PROVIDERS**

POLICY MAKERS




NO. OF CHAMPIONS^{*} 70,767

SOCIAL FOLLOWERS^{*}

30.5K 11.1K 9.7K

REVENUE: FISCAL YEAR 2020





See page 14 for all of our FY20 financials.

\$5,306,744 JULY 1 - JUNE 30

LUKE PERRY'S NO-SHAVE TWEET NOVEMBER **CAMPAIGN** PERSONAL **FUNDRAISING** PAGES

RELENTLESS **PATIENT SUPPORT**



Your dollars supported patients dealing with colorectal cancer during COVID-19 and ensured they had access to medically reviewed resources.



"2020 has been a year unlike any other for me, as I have had to battle both cancer and COVID-19 simultaneously. What may seem to some like an insurmountable climb, Fight CRC provided me with the go-to resources and trusted information to make this year just another chapter in my journey. They even gave me a free mask, which showed that they care about my safety. They connected me with a community that understands me and have taught me what it means to be a relentless champion of hope."

Evan White Stage IV Survivor, diagnosed at age 24

COVID-19 RESPONSE

Two weeks after COVID-19 was declared a pandemic, we wanted to help patients. We kicked off a weekly series on social media called Wellness Wednesday, launched an online hub full of webinars, blogs and important links, and we made sure patients had BLUE face masks.

- 8.5K pageviews of the resources in 7 months. •
- Our toll-free hotline (In partnership with Cancer Support Community) extended its hours to help patients cope with fear, isolation, and social distancing.

FREE Mask from @fightcrc! NUCLEARNICOLE

8,000+ FREE MASKS GIVEN AWAY IN 2020 📕



"Early on, we knew patients, their families, and caregivers were going to be disproportionately impacted by the COVID-19 pandemic. Studies have since shown that cancer patients are twice as likely to become infected than the general population, and they are significantly more likely to die from COVID-19 once infected. This has put an additional burden on patients who were already in a fight. That's why we quickly produced masks for our community and gave them away for FREE. We wanted to encourage our champions to stay hopeful, and to focus on things they could control, like wearing a mask, during challenging times."

Anjee Davis President of Fight CRC

RELENTLESS CLIMBERS

- 120 hikers joined our August 2019 Climb in Colorado and raised \$91,034.
- Due to COVID-19, we transformed the 2020 event into a virtual climb, which ultimately grew it to 873 participants from 47 states who raised \$257,913 (a 183% increase!).

183% INCREASE IN 2020 🗸

NEW AMBASSADORS

COVID-19 didn't stop us from championing a new class of relentless ambassadors who are passionate about raising awareness with their stories.

We onboarded 24 new ambassadors, bringing the total we've trained to 141.

THE GO-TO RESOURCE FOR PATIENT EDUCATION

When patients went looking for colorectal cancer education, they came to us!

- Total No. resources downloaded*: 7.4K
- No. website visits*: 737.7K users and 887K sessions
- Launched our new-and-improved patient magazine, Beyond Blue, which won a GOLD Aster Award.
- Teamed up with Komodo Health to advance early screening, biomarker testing, and to target health care providers who serve families with the greatest need. *Between July 1, 2019-June 30, 2020

737,700 WEB USERS SINCE 2019 📕



"To better target our education and outreach efforts, we turned to Komodo's technology which involves AI-powered analytics that track physician referrals. Our plan is to expand our reach into local communities by providing our no-cost, medically reviewed resources."

Anjee Davis President of Fight CRC

CLIMB FOR A CURE



141 **TOTAL NUMBER OF FIGHT CRC AMBASSADORS TRAINED TO DATE**



CHAMPIONING ADVOCACY



Your support activated Fight CRC's champions as we called on Congress, launched state-level advocacy, and raised awareness.



"I'm a relentless champion because advocacy gives me hope and it's how I've continued being a voice for my daughter Robyn. Even though we didn't go to D.C. this year, I virtually raised my voice on Hill Day and have continued to take action. I'm pleased to see that stories like my daughter's, who was diagnosed with stage IV colorectal cancer at age 31, are getting noticed and remembered on the Hill, and that early-onset colorectal cancer is starting to influence policy-makers' decisions. I'm thrilled that the Catalyst program is making waves in my state of Arkansas. Advocacy brings purpose to my pain."

Mary Schmid Arkansas, Caregiver

PUTT FOR PREVENTION

Our team coordinated stage I survivor and PGA TOUR professional golfer Tom Lehman's visit to Washington, D.C. We hosted a putting event for Members of Congress and their staff where Lehman told his story and discussed the importance of screening.

- Lehman met with several Members of Congress as well as President Trump.
- A few months following his visit, the House passed • the Medicare Loophole Bill.



CALL-ON CONGRESS PIVOTS

In early March, we were one of the FIRST groups to switch our in-person Call-on Congress to a virtual event. Because we went virtual, we engaged more advocates than ever!

- 561 people engaged in the online training.
- 1,480 advocates sent 4,056 emails to Members of Congress on Virtual Hill Day.

4,056 EMAILS SENT TO CONGRESS



CATALYST STATE-BY-STATE ADVOCACY PROGRAM

This year *we launched* a competitive grant program supporting colorectal cancer policy change at the state level. Our goal is to accelerate progress by increasing access and reducing barriers to colorectal cancer screening.

- In the first year, Fight CRC provided funding and support to coalitions in:
 - Arkansas
 - California
 - Colorado
 - Louisiana
- California and Colorado introduced legislation to increase access to colorectal cancer screening.
- We hosted two virtual State Policy Action Planning Sessions with CRC advocacy organizations, public policy professionals, researchers, clinicians, and others, to discuss the challenges around enacting state-level policy to increase access to CRC screening.
- A new Advocacy Portal launched in June 2020 and has already seen 2,211 advocates sign up to take action in support of the colorectal cancer community.

FLEX YOUR VOTE

In preparation for the 2020 election and to engage immunocompromised patients, we developed the Flex Your Vote campaign to boost voter registration and participation. We are so proud of our relentless champions who made sure to vote in the November 2020 election! See what we did at FightCRC.org/Vote.

POLICY WINS

- House of Representatives passed the Medicare Loophole Bill!
- FY19 Appropriations Bill included language directing the National Cancer Institute to dedicate additional resources toward early-age onset colorectal cancer (EAO CRC) research
- Colorado's colorectal cancer screening legislation passed the House with bipartisan support.
- The federal government declared March as Colorectal Cancer Awareness Month. as well as 40 states. Puerto Rico. and the District of Columbia.



2,211 **ADVOCACY PORTAL SIGN-UPS SINCE JUNE 2020 LAUNCH CHECK IT OUT:** FIGHTCRC.ORG/CATALYST







HOPE-FILLED RESEARCH



We invested your dollars into projects focusing on cutting-edge research, with a special focus on early-age onset colorectal cancer (EAO CRC).



"As a researcher, we are getting better at prevention, early detection, and treatment of CRC every day. The dollars Fight CRC is investing in research will save lives. It may not be instant, as this process never is, but this organization understands the value that research plays and it's not only engaged in funding it, but it's convening researchers to discuss it and move it forward. This is making positive impacts for patients every day."

Heather Hampel Researcher and member of Fight CRC's Genetics and Family History Advisory Council



Fight CRC and the Colon Cancer Coalition awarded \$200,000 to Dr. Lisa Boardman, along with her team at Mayo Clinic, for biobank research.

Dr. Boardman is looking at samples of pre-colorectal cancer and colorectal cancer to better understand how a normal colon progresses into a polyp, and then (in some cases) into a cancer. This builds on her previous findings which showed there may be a difference in the biology between younger and older colorectal cancers.



WHAT'S A BIOBANK? A REPOSITORY THAT STORES BIOLOGICAL SAMPLES USED IN RESEARCH.

2ND ANNUAL SYMPOSIUM

In light of COVID-19, we turned our second annual Early-Age Onset International Symposium into a virtual event and partnered with the Jiménez Díaz Hospital in Madrid, Spain.

Goals of the Symposium:

- Better understand the current burden of early-age onset colorectal cancer.
- Explore high-impact research endeavors.
- Prioritize a collaborative path forward.

Save the Date! 3rd Annual EAO CRC Symposium will be June 24-25 (it's a virtual event).



Over 500 medical providers, researchers, patients, and patient advocates from over 17 countries attended!



EXPERT WORKGROUPS

We continued to convene experts twice a year to discuss priorities for CRC research.

- Immunotherapy Workgroup
- EAO CRC Workgroup

Hold your smart phone's camera over the code to meet the experts in our workgroups!

RESEARCH PAPER PUBLISHED

Our EAO CRC research paper was published in the journal *Gastroenterology* in July 2019.



"Successful research takes collaboration. This paper was the product of over 45 researchers putting their heads together to identify the major risk factors for EAO CRC that are necessary to explore. This work is the roadmap that will help inform research funding priorities and policy decisions for those affected by EAO CRC."

Andrea (Andi) Dwyer

Advisor to Fight CRC Research and Patient Education and Director of the Colorado Cancer Screening Program (CCSP) at the Colorado School of Public Health

RELENTLESS CHAMPIONS IN THE FIGHT AGAINST COLORECTAL CANCER

SO OTHER FAMILIES WILL AVOID THE PAIN

When colorectal cancer claimed the lives of Josien Jurriens at age 40 and her husband, Ton Jurriens, at age 50, Josien's brother and sister-in-law looked for a place to find hope. Watching their young niece, Renske, and nephew, Rutger, grow up without their parents fueled Ron and Martha Doornink to do whatever they could to help other families avoid the same pain.

"It took some time for us to pull out of the stage where you feel powerless, but gradually it dawned on us that we had to FIGHT the disease that took Josien and Ton's lives, and the lives of so many others," said Ron Doornink, Fight CRC Board Member and administrator of the Ron and Martha Doornink Foundation. "What better way than to support scientists who are on the frontline of this battle?"

As a business professional skilled in board leadership and financial investments, Ron understood the importance of finding the right research partner. After meeting the Fight CRC team in 2015 and learning about how we fund research, convene the world's leading experts, and engage directly in the research process, he became a relentless champion of hope and chose to invest his family foundation's funds into Fight CRC research efforts.

"Our enemy is colorectal cancer and Fight CRC is the right organization to help us fight this enemy with laser-like precision because that is their one and only mission," said Ron.

Today, Renske and Rutger are in their late twenties and doing well. Their colon health is being carefully monitored, of course. Meanwhile, Ron and Martha remain committed to keeping the legacy of their loved ones alive. One way they do so is by funding innovative research, especially studies aimed at early-age onset colorectal cancer.

Beginning in 2020, the Ron and Martha Doornink Foundation launched a new grant and awarded its first recipient, Dr. Lisa Boardman, Assistant Professor of Medicine, Mayo Clinic College of Medicine, with \$150,000 to expand her biobank research. Dr. Boardman's earlier research findings indicated there may be important differences in biology between colorectal cancer in young adults versus older adults. The Doorninks' grant received a \$50,000 match from funds raised by Dan and Paula McQuillen, a couple who lost their 34-year-old son to stage IV colorectal cancer in 2011 and donated the proceeds to the Colon Cancer Coalition.

"Martha and I think of Fight CRC as the kickstarter of colorectal cancer research funding," said Ron. "They support innovative early-stage research that is promising but does not yet qualify for funding by the government or medical companies. We are 100% convinced that the battle can be won through research and we hope you will join our FIGHT!"

HOPE-FILLED RESEARCH



The dollars you donated to Fight CRC directly impacted families who are searching for clinical trials and others who are looking for ways to give back and get involved in the research process.

PATIENTS SPEAK OUT

To explore the impact of COVID-19 on the colorectal cancer community. we partnered with Komodo Health and Colontown to undertake a study of colorectal cancer care volumes, behaviors, and attitudes. We surveyed our relentless champions of hope about their experiences during COVID-19.

KEY FINDINGS

The total number of colonoscopies and biopsies performed declined nearly 90% 90% by mid-April compared to the same period last year.

- New colorectal cancer diagnoses were down more than 32% by mid-April 32% and colorectal cancer surgeries fell by 53% compared to year-ago figures.
- Nearly 40% of colorectal cancer patients and caregivers reported disruptions in their care, **40%** especially as it relates to in-person visits and imaging. Of these, 25% said they did not know when their care would be rescheduled, and 34% said their visits changed to telehealth.
- A majority (78%) of colorectal cancer patients feel nervous, anxious, or on edge, and 57% reported **78%** they are concerned about contracting COVID-19; 20% report feelings of isolation.

Our findings catalyzed conversations around the need for public health and health system policies that prioritize vulnerable populations and for those whom a delay in care is most likely to result in poor outcomes.

The data was published in Reuters and The New York Times. REUTERS Che Sew Jork Eimes

CHAMPIONING ADVOCATES

Our Research Training Advocacy and Support (RATS) program continued to connect patients to the science.

- Trained 11 new research advocates, bringing our total trained to over 40.
- Advocates serve on distinguished panels with National Cancer Institute (NCI), Department of Defense (DoD), and other groups!


FIERCE RESEARCH ADVOCATES

Survivor Wenora Johnson was appointed to FORCE's Board of Directors. FORCE is a community of peers and professionals who advocate for awareness, access to care, and better treatment and prevention options for the millions of individuals and families facing hereditary breast, ovarian, pancreatic, prostate, colorectal, and endometrial cancers.



"The pandemic allowed me to make time for being a fierce research advocate on a virtual level. Taking advantage of opportunities that would have required an in-person touch, I reached out to groups and asked to contribute virtually. I was given more opportunities to have my voice heard and to participate in online discussions. I've also joined FORCE's Board of Directors!"

Wenora Johnson CRC Stage III Survivor + FORCE Board of Directors



FIGHT COLORECTAL CANCER

SURVIVOR LEE JONES APPOINTED TO THE NCI CENTRAL **INSTITUTIONAL REVIEW BOARD (CIRB)**

Lee Jones has been appointed as a member of the NCI CIRB. This board reviews and ensures patient protection for all clinical trial applications submitted by the five National Clinical Trial Network organizations (such as the SWOG Cancer Research Network) and a number of other research organizations. The appointment enables Lee to review trials initiated by all the major U.S. cancer research centers. He chose to join the Early Phase Emphasis Board to participate in the novel trials that could have the highest potential to benefit patients of all cancer types.



"Many thanks to Fight Colorectal Cancer's RATS program that got me interested in cancer research advocacy and opened up opportunities like this to help other cancer patients experience the same positive outcome I've had."

Lee Jones

RATS ACADEMY

RATS Academy gives our advocates the opportunity to engage and interact with top researchers who are at the forefront of finding the best treatment options for CRC patients.



No. of research advocates who attended a RATS Academy at Promega Corp. in October 2019.

No. of advocates who attended an academy with Proteus in January 2020.

Due to COVID-19, a virtual academy was held in April 2020 with researchers at MD Anderson Cancer Center.

CLINICAL TRIAL FINDER

We continued investing in the maintenance of our web-ba clinical trial finder and companion app, and we created educational materials about how to use it and the benefits of clinical trials.

- Hired research advocate Maia Walker to lead its curation.
- In FY20, the Trial Finder saw 3,400 users who performed nearly 5,000 searches; new lifetime totals: 24,000 users and 40,000 searches since its launch in 2017.

40,000 SEARCHES SINCE 2017 🗸


RELENTLESS CHAMPIONS IN THE FIGHT AGAINST COLORECTAL CANCER

CRC Stage III Survivor + NCI Central Institutional Review Board



ased	





2020 FINANCIALS

BALANCE SHEET Fiscal year ending June 30, 2020

ASSETS	2020	2019	
CURRENT ASSETS			
Cash	\$2,821,093	\$2,181,074	
Contribution Receivable	\$2,243,020	n/a	
Prepaid Expenses	\$47,505	\$3,890	
Inventory	n/a	n/a	
TOTAL (CURRENT ASSETS)	\$5,111,619	\$2,184,964	
FIXED ASSETS			
Furniture & Equipment	\$12,351	\$12,452	
Computers	\$49,306	\$26,000	
Website Design & Maintenance	\$78,330	\$71,700	
Leasehold Improvements	\$614	\$614	
Less Accumulated Depreciation	-\$38,554	-\$40,762	
TOTAL FIXED ASSETS	\$102,047	\$70,004	
OTHER ASSETS			
Security Deposit	\$1,650	\$1,650	
TOTAL OTHER ASSETS	\$1,650	\$1,650	
TOTAL ASSETS	\$5,215,316	\$2,256,618	

LIABILITIES	2020	2019	
CURRENT LIABILITIES			
Accounts Payable	\$33,521	\$7,561	
Accrued Vacation	\$53,428	\$28,493	
Accrued Payroll	\$49,031	\$28,617	
Credit Card Payable	\$13,474	\$45,168	
PPP Loan	\$232,004	n/a	
TOTAL (CURRENT LIABILITIES)	\$381,460	\$109,839	

EQUITY	2020	2019
Unrestricted	\$1,541,201	\$1,737,497
Temporarily Restricted	\$535,760	\$409,282
2020 Net Revenue	\$2,756,894	n/a
TOTAL NET ASSETS	\$4,833,856	\$2,146,779

TOTAL LIABILITIES AND EQUITY	\$5,215,316	\$2,256,618	
---------------------------------	-------------	-------------	--

FEDERAL TAX ID: 20-2622550 COMBINED FEDERAL CAMPAIGN (CFC): #78265

REVENUE

\$26,566	INTEREST & OTHER
\$6,209	PRODUCT
\$226,213	PROGRAM FEES
n/a	IN-KIND DONATIONS
\$350,895	INDIVIDUAL DONATIONS
\$199,976	BOARD DONATIONS
\$563,738	TRIBUTE GIFTS
\$3,933,144	PHARMA/CORP/FOUNDATION

\$5,306,744 TOTAL

STATEMENT OF ACTIVITIES Fiscal year ending June 30, 2020

INCOME	2020	2019	PROGRAM & SUPPORT SERVICES EXPENSES	2020	2019
Contributions Unrestricted	\$2,960,973	\$1,737,497	PROGRAM SERVICES		
Contributions Restricted	\$459,052	\$409,282	Research	\$355,808	\$365,15
Product Sales	\$6,209	\$35,640	Patient Education	\$522,703	\$256,55
In-kind donations	n/a	\$300,000	Policy	\$608,765	\$476,22
Interest Income	\$20,342	n/a	Awareness	\$659,667	\$962,48
Event Revenue	\$226,213	\$12,134	TOTAL (PROGRAM EXPENSES)	\$2,146,944	\$2,060,4
Other Income	\$6,223	\$4,824	SUPPORTING SERVICES		
т	\$3,679,015	\$2,499,377	Management	\$246,942	\$184,57
Fight CRC was awarded a \$2,722,500 multi-year, unrestrict-			Fundraising	\$155,962	\$233,34
ed grant from Exact Sciences, payable in installments of \$544,500 over a 5-year period. Accounting standards require the grant be recognized in the year awarded as all conditions related to the grant have been met. The entire \$2,722,500 is included in income for FY19 even though the cash associated			TOTAL (SUPPORTING EXPENSES)	\$402,905	\$417,91
			TOTAL EXPENSES	\$2,549,849	\$2,478,3

with the grant will be received in installments.

PROGRAM REVENUE

\$1,115,309	GENERAL
\$628,235	FUNDRAISING
\$384,750	RESEARCH
\$239,000	PATIENT EDUCATION
\$2,851,569	POLICY
\$87,878	AWARENESS

N

\$5,306,744 TOTAL

To cure colorectal cancer, it's going to take all of us! Here's a glimpse into THE PATH TO A CURE the progress we've made so far and why we must keep pushing for a cure! 1896 1966-69 1999 1913 1932 1966 1996 1962 Researchers begin to study bereditary colorectal cancer Cuthbert Dukes devises a lenry T. Lynch identifies familie iromi Shinya and William Wolf Patients and caregivers found the Colon Cancer Alliance English Sir Jonathan Hutchinson lays the ion system for the with an inherited susceptibility staging of colorectal cancers to cancers of the colon and treated with FOLF polyp removal techniques indwork for studying uterus, what is now known 20 disease by describing as Lynch Syndrome SPE the association of colorecta d (🚮 mucosal pigmentation and gastrointestinal 10 - Theory cancer 82.0 polyposis alliance 2004 2001 2001 2001 2000 2000 2000 2004 The American College of Medicare begins paying The first Presidential The National Colorectal TODAY show host Katie Couric's (Avastin[®]) and cetuximab (ERBITUX[®]) ELOXATIN[®]) and patients an treated with FOLFOX loda[®]), the first oral colore for average-risk beneficiarie Proclamation for Colorectal Cancer Roundtable (NCCRT) on-air colonoscopy creates astroenterology recommend he first colonoscopy screenin Cancer Awareness Month is established colonoscopy screening an uptick in screening protocol: every 10 years is issued T Eloxatin Oxaliplatin Singlal _____ Colorectal NATIONAL Eloxatin* Oxaliplatin Smjal Xeloda' 500 mg tile-casted tables Capecitable 500 mg Dat et IHR **10 YEARS** *Medicare* 20 ml ----- 10 ml 50 mg E Ter wat ROUNDTABLE 2005 2008 2008 2010 2012 2012 2014 2015 Fight CRC awards first The FDA approves trifluridir and tipiracil (LONSURF®) cates, led by Nancy Roach The World Health Organizatio Congress includes colorectal Congress introduces the first The FDA approves regorafenil (STIVARGA[®]) and aflibercept NCCRT and its members launch earch grant to Dr. Yaguang Xi cancer on the list of cancers 80% by 2018, a national ound Fight Colorectal Cancer (WHO) ranks colorectal cance noving Barriers to Colorecta (Fight CRC) and attend a lobby as the #2 cancer killer of mer o study micro RNA through the eligible for the Department Cancer Screening Act campaign to increase of Defense (DoD) Peer Reviewed Cancer Research in partnership with multipl and women combined in the developed world Lisa Fund screening rates cancer organizations Program (PRCRP) Lonsurf. 20mg/8,19mg Stivarga Inpedidente King R F!GHT World Health Organization CDMRP Organization COLORECTAL CANCER 2020 2019 2019 2019 2018 2017 2017 2017 The American Cancer Society Fight CRC forms the Early-Age Onset Workgroup and publishes "A summary of the Fight Congress directs the NCI Fight CRC partners with the Cancer Research Institute Fight CRC launches MSS-CRC e FDA approves penbrolizur (KEYTRUDA[®]), first immun Congress passes an appropria Clinical Trial Finder in partner-ship with Dr. Tom Marsilje, nbination for patient to devote more resources ons bill increasing the Nationa ACS) lowers the recommende (CRI) to publish "A Blueprin of Health (NIH) fundir screening age to 45 for to early-age onset Colorectal Cancer working meeting: Exploring risk factors and etiology of sporadic colorectal cancer by \$2.6 billion, with a \$296 illion increase for the Nationa average-risk individuals to Advance Immuno-Oncology (IO)" and awards a \$200,000 ho gets featured in Newswee Cancer Institute (NCI) grant to Dr. Cynthia Sears to FDA early-age onset colorectal cancer" in Gastroenterology American Cancer Society® estigate the microbiome wit unds donated from Gordon NATIONAL NIH A Street CANCER Cole's family F!G INSTITUTE 2020 2020 2020 The Ron and Martha Doornink Fight CRC is the first to publish The United States Preventive Services Task Force (USPSTF) amily Foundation, in partner a ČOVID-19 study with Komodo Ĵij provides a public comment with Fight CRC and the Health looking at the impact period, announcing their plan o lower the colorectal cance Cancer Coalition, award on colorectal cancer screenir \$200,000 to Mayo Clinic's and treatment, which gets Dr. Lisa Boardman to establish a polyp biobank to better eatured in *Reuters* and *The New York Times* screening age to 45 for average-rise individuals RELENTLESS MORE **CHAMPIONS** erstand early-age onset **A CURE** colorectal cancer The New York Times





THANK YOU TO OUR SPONSORS AND SUPPORTERS!



Hold your smart phone's camera over this code to see all of our sponsors!



Special thank you to the Fight CRC Ambassadors who are featured in the photography throughout this publication!





















134 Park Central Square, Suite 210 • Springfield, MO 65806



